Citadel Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Citadel Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-525	Closed	-$27K	–	14674
2021 Q2	$27K	Buy	+525	New	+$26.3K	﹤0.01%	13501

Other funds holding TTNP

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GWSA

Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's TTNP Position: Q3 2025 in Review

Citadel Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 12,069 shares — an estimated $50.7K sold.

Citadel Advisors first reported a position in TTNP in Q2 2016 and held it in 12 quarters. The position peaked at $179K in Q2 2021. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

Citadel Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 12,069 Titan Pharmaceuticals shares in Q3 2025, an estimated $50.7K.
Citadel Advisors first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 12 quarters.
Citadel Advisors's Titan Pharmaceuticals position peaked at $179K in Q2 2021.
18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.